| Pack Size/Qty | Price | Unit Price | |
| 90 Rotacap/s | $26.00 | $0.29 | |
| 60 Rotacap/s | $18.50 | $0.31 | |
| 30 Rotacap/s | $11.10 | $0.37 |
Generic Name : Salmeterol and Fluticasone Propionate
Brand Name : Advair Rotacaps
Manufacturer Name : Cipla Ltd - Pharmaceutical Company
Product Code : CRX 261
Delivery Days : 10 to 15 working days
Packaging : Rotacaps/s
Prescribed For : Respiratory Tract Disorders, Asthma
Seroflo Rotacaps 50 mcg/100 mcg is a combination inhaler medication designed to manage and treat respiratory conditions, particularly asthma and chronic obstructive pulmonary disease (COPD). This pharmaceutical product represents a harmonious blend of two active ingredients – fluticasone propionate and salmeterol xinafoate – each playing a crucial role in addressing different aspects of respiratory disorders. This comprehensive review will delve into the composition, mechanism of action, indications, dosage, potential side effects, and other relevant aspects of Seroflo Rotacaps 50 mcg/100 mcg.
The Seroflo Rotacaps 50 mcg/100 mcg inhaler contains two primary active ingredients:
Fluticasone Propionate (50 mcg): Fluticasone propionate is a corticosteroid with potent anti-inflammatory properties. It acts locally in the lungs to reduce inflammation, which is a key component of asthma and COPD. By inhibiting the release of inflammatory mediators, fluticasone helps alleviate symptoms such as wheezing, shortness of breath, and chest tightness.
Salmeterol Xinafoate (100 mcg): Salmeterol is a long-acting beta-2 adrenergic agonist (LABA). It functions by relaxing the smooth muscles in the airways, leading to bronchodilation. This action helps improve airflow and makes breathing easier. Salmeterol is particularly beneficial in preventing bronchoconstriction, a common feature in asthma and COPD.
The combination of fluticasone propionate and salmeterol in Seroflo Rotacaps synergistically addresses the multifaceted nature of respiratory conditions. Fluticasone reduces inflammation by inhibiting the production of inflammatory proteins, while salmeterol promotes bronchodilation by activating beta-2 receptors on the smooth muscle cells of the airways. This dual action helps control symptoms and improves overall lung function.
Indications:
Seroflo Rotacaps 50 mcg/100 mcg is primarily indicated for the management of asthma and COPD in patients who require both a corticosteroid and a long-acting beta-2 agonist. It is suitable for individuals whose conditions are not adequately controlled by a single medication. The combination therapy enhances efficacy and minimizes the risk of exacerbations.
The appropriate dosage of Seroflo Rotacaps 50 mcg/100 mcg is determined by the severity of the respiratory condition and the patient's individual response. It is crucial to follow the prescribed dosage and administration instructions provided by the healthcare professional. Generally, the inhaler is administered twice daily, with each dose separated by approximately 12 hours.
The Rotacaps are designed for use with a specific inhaler device, which facilitates the delivery of the medication directly into the lungs. Patients need to follow the instructions for loading the Rotacaps into the inhaler device and inhaling the contents properly.
As with any medication, Seroflo Rotacaps may cause side effects, although not everyone experiences them. Common side effects include:
Throat irritation: Patients may experience mild irritation or a sore throat.
Hoarseness: Fluticasone, being a corticosteroid, can sometimes cause hoarseness of the voice.
Headache: Some individuals may experience headaches, though these are usually transient.
Nausea: Nausea is a less common side effect but may occur in some cases.
Tremors: Salmeterol, as a beta-2 agonist, may cause mild tremors in some individuals.
Serious side effects are rare but can include paradoxical bronchospasm (sudden and severe narrowing of the airways), allergic reactions, and cardiovascular effects. It's important for patients to promptly report any unusual or severe symptoms to their healthcare provider.
Precautions and Contraindications:
Certain precautions and contraindications should be considered before initiating Seroflo Rotacaps therapy. It is contraindicated in patients with a known hypersensitivity to fluticasone, salmeterol, or any of the excipients in the formulation. Additionally, healthcare providers should exercise caution in prescribing this medication to individuals with a history of cardiovascular disorders, including arrhythmias.
Seroflo Rotacaps 50 mcg/100 mcg stands as a valuable therapeutic option for individuals grappling with the challenges of asthma and COPD. Its combination of fluticasone propionate and salmeterol xinafoate addresses the underlying inflammatory processes and provides bronchodilation, offering a comprehensive approach to symptom management.
As with any medication, it is crucial for patients to adhere to the prescribed dosage and administration instructions and to report any adverse effects promptly. Regular follow-ups with healthcare providers are essential to monitor treatment efficacy and make any necessary adjustments to the therapeutic plan.
In summary, Seroflo Rotacaps 50 mcg/100 mcg represents a milestone in respiratory care, embodying the progress made in developing effective combination therapies for chronic respiratory conditions. As we reflect on its composition, mechanism of action, indications, and potential side effects, we acknowledge its role in improving the quality of life for individuals navigating the challenges of asthma and COPD.
